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Abstract 
Review on epithelioid hemangioendothelioma with 
data on clinics and the genes implicated. 
Identity 
Other names 
Hemangiosarcoma 
Hemangioendothelioma 
Hemangioendothelial sarcoma 
Epithelioid angiosarcoma 
Epithelioid sarcoma-like hemangioendothelioma 
Pseudomyogenic hemangioendothelioma 
Note 
Vascular tumors of bone range from benign 
hemangioma to highly malignant angiosarcoma. 
They are composed of tumor cells forming vascular 
spaces. In 1943, Stout defined the diagnostic 
criteria for malignant vascular tumors, which he 
named hemangioendothelioma. Since 1994, the use 
of the term "hemangioendothelioma" referring to 
vascular tumors of bone has decreased due to the 
need of a more accurate classification.  
According to the WHO Classification of Tumors of 
Soft Tissue and Bone and the ISSVA classification, 
the term "hemangioendothelioma" connotes 
intermediate malignancy, except in the context of 
epithelioid hemangioendothelioma, which is 
described as a distinct entity and classified as 
malignant. We consider the name epithelioid 
hemangioendothelioma of bone for low-grade 
malignant endothelial vascular neoplasms of bone 
with tumor cells showing endothelial 
differentiation, and a biologic behavior between 
that of hemangioma and angiosarcoma. 
 
Clinics and pathology 
Note 
Pathogenesis unclear. Highly malignant vascular 
tumors of bone (angiosarcomas) may arise at sites 
of prior radiation. 
Epidemiology 
Epithelioid hemangioendothelioma of bone account 
for less than 1% of malignant bone tumors. It may 
occur at any age, although approximately half of the 
cases tend to occur during the second and third 
decades of life. Males and females are 
approximately equally affected. The tumors show a 
wide skeletal distribution affecting the long tubular 
bones of the extremity and the axial skeleton, 
mainly the spine. The lower extremities are 
predominantly affected, with more than half of the 
lesions located in the tibia or femur; spinal lesions 
account for less than 10% of the cases. 
Approximately one third are multicentric within a 
bone or multifocal, within multiple bones with 
lesions randomly distributed throughout the 
skeleton or clustered in an anatomic region, such as 
a single extremity. However, the distinction 
between multifocal and metastatic disease is not 
clear. In general multifocal disease is thought to be 
limited to a specific anatomic region (i.e., bones of 
the same limb) with variable involvement of 
individual osseous elements. Thus it is debatable 
whether disease in the femur and cervical spine 
may be considered multifocal, as opposed to 
metastatic given that this tumor has capacity of 
metastasizing hematologically. However, when 
disease is located in the distal femur or patella, is 
easier to consider it multifocal. 
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Figure A: Sagittal T2-weighted magnetic resonance imaging of the sacrum shows osteolysis and destruction of the coccyx with 
anterior soft tissue mass. Biopsy showed epithelioid hemangioendothelioma of the coccyx. Figure B: Sagittal T1-weighted 
magnetic resonance imaging of the thoracic spine of a patient with recurrent epithelioid hemangioendothelioma of the T3 
vertebra. 
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Figure C: Photomicrograph (stain, hematoxylin and eosin; original magnification, 10x) shows epithelioid cytomorphology with 
variably solid or vasoformative architecture and tumoral cells with large, pleomorphic and mildy hyperchromatic nuclei with 
evident nucleoli. Vascular cavities are variable and matted with neoplastic endothelial cells. Figure D: Photomicrograph (stain, 
hematoxylin and eosin; original magnification, 20x) shows blood filled cavities of different caliber rimmed by plump endothelium 
with epithelioid appearance. CD31 staining of the endothelium of the tumoral vessels is typically cytoplasmic. 
 
 
Clinics 
Clinical symptoms include pain and possible 
association with a palpable tumor mass. 
Neurological symptoms may occur in patients with 
spinal involvement. Tumor growth may be rapid or 
slow, and infiltrative. 
Imaging 
The imaging appearance of epithelioid 
hemangioendothelioma of bone is non-specific.  
The tumors are purely lytic, poorly marginated with 
varying degrees of peripheral sclerosis.  
A soft tissue mass is often associated with less well 
differentiated tumors. Clustering of multifocal 
lesions in a single anatomic location suggests the 
diagnosis of a vascular neoplasm. 
Pathology 
Gross pathology: Macroscopically, epithelioid 
hemangioendothelioma of bone tends to be firm 
and tan-white. The tumor can erode the cortex and 
extend into the soft tissue. 
Micropathology: Microscopically, the tumor is 
composed of anastomosing cords, solid nests, and 
strands of endothelial cells that may sometimes 
form narrow vascular channels. The small capillary-
sized tumor vessels can mimic small reactive 
vessels of granulation tissue. The epithelioid cells 
tend to have eosinophilic cytoplasm which may 
show vacuolization and sometimes signet ring-like 
appearance. The connective tissue stroma shows 
significant myxoid and hyalinized appearance.  
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The nuclei of the neoplastic cells show varying 
degrees of pleomorphism and anaplasia. 
Although many variants of hemangioendothelioma 
have been reported, the striking features of growth 
of epithelioid hemangioendothelioma of bone are 
the formation of atypical endothelial cells (marked 
nuclear atypia, mitotic activity, spindling of cells 
and necrosis) arranged in cords, in greater numbers 
than required to line the vessels with a simple 
endothelial membrane, and the formation of 
vascular tubes with a delicate framework of 
reticulin fibers with a marked tendency for their 
lumens to anastomose. On hematoxylin and eosin 
stains the neoplastic epithelioid endothelial cells are 
embedded in a hyalinized (deep pink) or chondroid-
like (light blue) matrix. No tumor should be 
considered an epithelioid hemangioendothelioma of 
bone unless these criteria are present. 
Immunophenotype: The endothelial cells 
uniformly express vimentin and many cells stain 
with antibodies to Factor VIII, CD31, CD34, and 
Ulex Europaeus. Epithelioid malignancies may also 
express cytokeratins and EMA. 
Ultrastructure: The endothelial cells contain 
Weibel-Palade bodies, but are generally difficult to 
find in poorly differentiated tumors. Cytoplasmic 
filaments are abundant. 
Treatment 
Surgical: Patients with epithelioid 
hemangioendothelioma of bone may be cured by 
surgery, with or without other treatments such as 
chemotherapy, radiation therapy and embolization. 
A possible major role for wide surgery should be 
considered for these tumors whenever this choice 
does not involve high morbidity or poor functional 
results. 
Radiation therapy: Adjuvant radiation therapy is 
advocated to decrease the risk of local recurrence. 
The risk for postradiation complications should be 
considered. 
Embolization: As a vascular tumor the potential 
for intraoperative blood loss is significant. To 
lessen this complication, patients should have an 
angiographic evaluation and selective embolization 
when feasible. 
Evolution 
Outcome: The reported local recurrence rate is up 
to 13%. Wide tumor resection has been related with 
a lower risk for local recurrence; however, a 
statistically significantly higher survival to local 
recurrence has not been shown in multivariate 
analysis. A median survival of 21 months, a 5-year 
survival of approximately 33%, and a metastatic 
rate of up to 31% has been reported. It is difficult to 
establish correctly which patient had bone 
metastasis and which patient had progression of the 
disease in the multifocal form. In the absence of a 
genetic analysis, patients with unifocal tumors that 
developed bone lesions after treatment should 
probably be considered as tumor progression in 
multifocal form. 
Prognosis 
The histological degree of differentiation as 
evaluated pathologically by the histological pattern 
of the tumor and the cytologic atypia of the 
neoplastic endothelial cells, and the presence of 
unifocal or multifocal tumor are the most important 
prognostic factors.  
The survival advantage for the patients with 
multifocal tumors may in part be related to the fact 
that multifocal tumors show better differentation. 
Conventionally, multifocal disease in a tumor with 
atypia would be considered a metastatic deposit, 
whereas when it occurs in tumors with entirely 
benign features it is considered a multifocal 
process. Additionally, tumor location in the axial 
skeleton and limb girdles probably precludes good 
prognosis because it is difficult to obtain adequate 
surgery, or multifocal tumors with poor outcome 
represent tumors with biologic behavior closer to 
angiosarcoma. 
Genetics 
Note 
Two epithelioid hemangioendotheliomas have 
shown an identical chromosomal translocation 
involving chromosomes 1 and 3. 
Genes involved and 
proteins 
Note 
Recent identification of WWTR1-CAMTA1 fusion 
provides a powerful diagnostic tool that can be used 
to distinguish an epithelioid hemangioendothelioma 
of bone from a hemangioendothelioma. However, 
genetic hallmarks of hemangioendothelioma are 
still under investigation. 
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